Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

FDA approves Ascensia Diabetes’ app-enabled blood glucose monitoring system

The US Food and Drug Administration (FDA) has approved Ascensia Diabetes Care's latest glucose monitoring system, which features a smart blood glucose meter and app to help patients better understand their diabetes.

The easy-to-use blood glucose smart meter can be connected to a mobile device through Bluetooth connectivity.

The meter links to the Contour Diabetes mobile app, which collects, stores and analyzes patient blood glucose measurements delivered to it.

Blood glucose measurements will enable to identify patterns and trends, helping patients to understand how certain aspects of their daily activities affect their blood glucose.

Contour Net One system features smartLIGHT on the meter, which offers instant feedback on blood glucose results, reminders and alerts for better management of diabetes.

The company plans to commercialize Contour Net One system in the US in early 2017.

Ascensia Diabetes Care US head Robert Schumm said: “The system combines the remarkable accuracy of the Contour Next One meter with the easy-to-use features of the Contour Diabetes app and is designed to provide insights that may help people manage their diabetes in a better way."

"We believe the future of healthcare lies in connecting points of care. The first step in that journey for diabetes is to provide a connected system which can add value for people living with diabetes.”

Ascensia Diabetes Care was formed in this year through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings.

With around 1,700 employees, Ascensia Diabetes Care markets its products in around 125 countries.